Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...

The seven recipients are honored for cutting-edge research on topics ranging from the neurocognitive mechanisms of information processing to the connections between psychopathology and addiction.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

Alkermes Plc (NASDAQ:ALKS) reported strong financial results for the fourth quarter of 2024, surpassing earnings per share (EPS) and revenue forecasts. The company's EPS stood at $1.05, significantly ...

Recognizing global leaders who have gone above and beyond to move their industries—and the world—forward ...